Trials / Completed
CompletedNCT00075959
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
CHANT (Cerebral Hemorrhage And NXY Treatment) A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter, Phase IIb Study to Assess the Safety and Tolerability of Intravenous Infusion of NXY-059 in Adult Patients With Acute Intracerebral Hemorrhage (ICH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NXY-059 |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2004-01-14
- Last updated
- 2013-01-04
Locations
64 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00075959. Inclusion in this directory is not an endorsement.